全球病毒滅活市場規模（依方法、產品、應用、最終用戶、地區、範圍和預測）

病毒滅活市場規模及預測

2023 年病毒滅活市場規模價值為 6.8391 億美元，預計到 2031 年將達到 13.8946 億美元，2024 年至 2031 年的複合年增長率為 9.27%。滅活病毒意味著破壞病毒的結構和遺傳物質，使其失去傳染性並阻止其複製或傳播給他人。這可以透過多種方法實現，包括熱處理、化學暴露和輻照。病毒滅活在醫學、生物技術和醫療保健領域有著廣泛的應用。藥品製造中的病毒滅活可降低病毒污染的風險，保護源自動物或人體組織的生物製品，如疫苗、血液製品和重組蛋白。

此外，在醫療保健環境中，病毒滅活程序用於對醫療設備、表面和體液進行消毒，以限制病毒病原體的傳播並防止疾病傳播。

全球病毒滅活市場動態

主要市場驅動因子

慢性病發生率不斷上升：

癌症、愛滋病毒和肝炎等慢性和危及生命的疾病的發生率不斷上升，需要更有效的生物製藥治療。這種需求推動了病毒滅活市場的發展，因為它對於生物製劑和血漿衍生物的安全性和有效性至關重要。

嚴格的監理準則：

為了確保生物製藥不受病毒污染，包括FDA和EMA在內的全球監管機構都對其生產制定了嚴格的規定。遵守這些法規需要使用病毒滅活技術，刺激市場擴張。

生物技術的進步：

生物技術和藥物研發的快速發展，帶動了疫苗、治療性蛋白質和單株抗體等生物製藥生產的擴大。這些產品需要病毒滅活以確保安全，從而推動了對病毒滅活技術的需求。

不斷成長的生物製劑和生物相似藥市場：

生物製劑和生物相似藥的市場正在擴大，因為它們在治療各種疾病方面很有效，並且需要嚴格的安全措施，包括病毒滅活。這種需求是病毒滅活市場的主要驅動力，因為產品安全對於監管部門批准和公眾信心至關重要。

主要問題

成本高、資源密集：

實施病毒滅活技術耗時又費錢，需要在技術和合格人員方面進行大量投資。對於中小型製藥和生技公司來說，這些高額投資是令人望而卻步的，限制了它們在市場上的競爭力。

病毒突破的風險：

儘管有嚴格的病毒滅活程序，但仍有可能因變異或出現不熟悉的病毒而出現病毒。這種風險使得人們需要不斷研究和開發以提高滅活方法的有效性，從而增加生物製藥製造的複雜性和成本。

主要趨勢

採用新技術：

病毒滅活市場擴大採用新技術，包括 UV-C 照射、高溫、短時 (HTST) 處理和先進的化學方法。這些技術正在提高效率和安全性，克服傳統方法的局限性，從而推動市場成長。

更重視自動化：

為了提高可重複性、消除人為錯誤和增加吞吐量，自動化病毒滅活程序的趨勢日益增長。自動化還有助於遵守監管標準並使程序更有效率、更具成本效益。

進入新興市場：

由於生物製藥行業的擴張、醫療保健支出的增加以及對生物製劑安全性的日益擔憂，病毒滅活市場正在擴展到新興經濟體。此次擴張為我們傳統市場之外的新的市場成長前景開闢了機會。

進階分析整合：

高級分析技術越來越多地被融入病毒滅活過程中，從而實現即時監測和控制。這種連結將使滅活方法更加準確和快捷，提高安全性和法規遵循性，同時也刺激市場創新。

目錄

第 1 章全球病毒滅活市場簡介

市場概況
• 研究範圍
• 先決條件

第 2 章執行摘要

第 3 章：經過驗證的市場研究方法

• 資料探勘
• 驗證
• 主要來源
• 資料來源列表

第 4 章全球病毒滅活市場展望

• 概述
• 市場動態
  • 驅動程式
  • 阻礙因素
  • 機會
• 波特五力模型
• 價值鏈分析

第 5 章全球病毒滅活市場（依方法）

• 概述
• 溶劑清洗法
• 巴斯德消毒法
• 其他

第6章 全球病毒滅活市場（依產品）

• 概述
• 試劑盒和試劑
• 服務
• 系統與配件

第 7 章全球病毒滅活市場（依應用）

• 概述
• 血液和血液製品
• 細胞和基因治療產品
• 幹細胞產品
• 紙巾和紙巾產品
• 疫苗和治療

第 8 章全球病毒滅活市場（依最終用戶劃分）

• 概述
• 製藥和生技公司
• 合約研究組織
• 學術研究機構
• 其他

第 9 章全球病毒滅活市場（按地區）

• 概述
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 其他歐洲國家
  亞太地區
  • 中國
  • 日本
  • 印度
  • 其他亞太地區
• 世界其他地區
  • 拉丁美洲
  • 中東和非洲

第 10 章全球病毒滅活市場的競爭格局

• 概述
• 各公司的市場排名
• 主要發展策略

第 11 章 公司簡介

• Sartorius AG
• Clean Cells
• Danaher Corporation
• Charles River Laboratories
• Merck KGaA
• Rad Source Technologies
• Parker Hannifin Corporation
• Viral Inactivated Plasma Systems SA
• SGS SA
• Texcell

第 12 章附錄

• 相關研究

Viral Inactivation Market Size And Forecast

Viral Inactivation Market size was valued at USD 683.91 Million in 2023 and is projected to reach USD 1389.46 Million by 2031 , growing at a CAGR of 9.27% from 2024 to 2031. Viral inactivation is the process of rendering viruses non-infectious by destroying their structure or genetic material, preventing them from replicating and infecting others. This is accomplished using a variety of ways, including heat treatment, chemical exposure, and irradiation. Viral inactivation has numerous applications, including medicines, biotechnology, and healthcare. Viral inactivation in pharmaceutical production protects biological products originating from animal or human tissues, such as vaccines, blood products, and recombinant proteins, by reducing the danger of viral contamination.

Additionally, in healthcare settings, viral inactivation procedures are used to sterilize medical equipment, surfaces, and bodily fluids, limiting viral pathogen transmission and preventing disease spread.

Global Viral Inactivation Market Dynamics

The key market dynamics that are shaping the Viral Inactivation Market include:

Key Market Drivers

Rising Prevalence of Chronic Diseases:

The rising prevalence of chronic and life-threatening diseases such as cancer, HIV, and hepatitis need more effective biopharmaceutical therapies. This need drives the Viral Inactivation Market since it is crucial to the safety and efficacy of biologics and plasma derivatives.

Stringent Regulatory Guidelines:

To ensure that biopharmaceutical products are free of viral contamination, regulatory bodies around the world, including the FDA and EMA, have established tight rules for their manufacturing. Complying with these rules involves the use of viral inactivation techniques, thereby fueling market expansion.

Advancements in Biotechnology:

Rapid advances in biotechnology and pharmaceutical R&D are resulting in greater manufacturing of biopharmaceuticals such as vaccines, therapeutic proteins, and monoclonal antibodies. These products require viral inactivation to ensure safety, which increases the demand for viral inactivation technology.

Growing Biologics and Biosimilars Market:

The rising market for biologics and biosimilars, driven by their efficacy in treating a variety of diseases, necessitates severe safety precautions, including viral inactivation. This need is a major driver of the Viral Inactivation Market, as product safety is critical for regulatory approval and public trust.

Key Challenges:

High Costs and Resource Intensity:

The execution of viral inactivation techniques is time-consuming and expensive, necessitating considerable investments in technology and qualified staff. These high expenditures are prohibitively expensive for smaller pharmaceutical and biotech companies, restricting their competitiveness in the market.

Risk of Viral Breakthrough:

Despite stringent viral inactivation procedures, there is always a possibility of viral emergence due to mutations or the presence of unfamiliar viruses. This risk needs continual research and development to improve the efficacy of inactivation methods, which increases the complexity and cost of biopharmaceutical manufacturing.

Key Trends:

Adoption of Novel Technologies:

The Viral Inactivation Market has experienced the use of novel technologies such as UV-C irradiation, high-temperature short-time (HTST) treatments, and sophisticated chemical approaches. These technologies increase efficiency and safety characteristics, overcoming the constraints of traditional approaches and boosting market growth.

Increased Focus on Automation:

There is a growing trend of automating viral inactivation operations to improve repeatability, eliminate human error, and boost throughput. Automation also helps to comply with regulatory standards, making procedures more efficient and cost-effective.

Expansion into Emerging Markets:

The Viral Inactivation Market is expanding into emerging economies, fueled by expanding biopharmaceutical industries, increased healthcare spending, and growing concern about biologics' safety. This expansion opens up new prospects for market growth beyond traditional markets.

Integration of Advanced Analytics:

Advanced analytics are increasingly being integrated into viral inactivation processes to provide real-time monitoring and control. This connection allows for more precise and fast inactivation methods, which improves safety profiles and regulatory compliance while also promoting market innovation.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Viral Inactivation Market Regional Analysis

Here is a more detailed regional analysis of the Viral Inactivation Market:

North America:

According to Verified Market Research, North America is estimated to dominate the Viral Inactivation Market over the forecast period. North America, particularly the United States, has a vast and sophisticated biopharmaceutical industry that leads in the development and production of vaccines, therapeutic proteins, and monoclonal antibodies. The magnitude and growth of this sector necessitate substantial viral inactivation methods, which drive regional demand.

The presence of severe regulatory organizations in the United States, such as the FDA, requires biopharmaceutical goods to meet stringent safety criteria, which include viral inactivation. This regulatory structure promotes high levels of compliance and the use of viral inactivation technology, hence promoting market dominance.

Furthermore, North America, particularly the United States, has one of the world's highest healthcare costs, indicating a significant investment in healthcare infrastructure, including innovative therapies and biopharmaceutical products. This investment encourages the use of sophisticated viral inactivation technologies, hence driving the market.

Asia Pacific:

The Asia Pacific region is estimated to exhibit the highest growth potential in the market during the forecast period. The Asia Pacific region's biopharmaceutical industry is expanding rapidly, spurred by increased expenditures in biotechnology and healthcare infrastructure. This expansion needs sophisticated viral inactivation technologies, which drive market growth in countries such as China and India.

Governments and the corporate sector in Asia Pacific are considerably boosting healthcare spending to improve public health services and access to innovative treatments. This investment promotes the development and use of safe biopharmaceutical products, particularly those that require viral inactivation.

Furthermore, there is a growing awareness in the region about the necessity of biological safety and the dangers of virus contamination. This knowledge is increasing the demand for viral inactivation technologies to ensure the safety of vaccinations, therapeutic proteins, and other biologics.

Europe:

Europe has advanced healthcare systems with robust regulatory frameworks overseen by authorities such as the European Medicines Agency (EMA). These systems require rigorous safety criteria for biopharmaceutical goods, emphasizing the importance of successful viral inactivation to ensure patient safety and product efficacy.

Europe is home to considerable biopharmaceutical research and development efforts, which are funded by both public and private funding. This investment promotes innovation in viral inactivation technologies and procedures, hence contributing to regional market growth.

Furthermore, in Europe, biopharmaceutical businesses, research institutes, and technology providers are highly collaborative and form collaborations. These agreements promote the exchange of knowledge and technology, such as viral inactivation, which improves the region's ability to address viral safety in biopharmaceuticals.

Global Viral Inactivation Market: Segmentation Analysis

The Viral Inactivation Market is Segmented based on Method, Product, Application, End-User, and Geography.

Viral Inactivation Market, By Method

• Solvent Detergent Method
• Pasteurization
• Others

Based on Method, the market is segmented into Solvent Detergent Method, Pasteurization, and Others. The solvent detergent method segment is estimated to grow at the highest CAGR within the Viral Inactivation Market due to its ability to inactivate encapsulated viruses while retaining the product's biological activity, making it a popular choice for the treatment of blood and plasma products, as well as certain biopharmaceuticals. The method's widespread acceptance can also be attributed to its simplicity, low cost, and comprehensive validation in assuring viral safety.

Viral Inactivation Market, By Product

• Kits and Reagents
• Services
• Systems and Accessories

Based on Product, the market is segmented into Kits & Reagents, Services, and Systems & Accessories. The kits & reagents segment is estimated to dominate the Viral Inactivation Market due to their widespread application throughout all stages of pharmaceutical and biopharmaceutical production, including research and development, manufacturing, and quality control. Kits and reagents are critical for efficiently and effectively carrying out viral inactivation activities, providing a balance of usability, cost-effectiveness, and dependability. Their high demand is exacerbated by the requirement for continuous viral safety testing in the production of vaccines, medicinal proteins, and other biologics.

Viral Inactivation Market, By Application

• Blood & Blood Products
• Cellular & Gene Therapy Products
• Stem Cell Products
• Tissue & Tissue Products
• Vaccines and Therapeutics

Based on Application, the market is segmented into Blood & Blood Products, Cellular & Gene Therapy Products, Stem Cell Products, Tissue & Tissue Products, and Vaccines & Therapeutics. The vaccines and therapeutics segment is estimated to dominate the market over the forecast period due to rising demand for vaccines and therapeutic medications, which is being driven by an increase in the global prevalence of chronic diseases and infectious outbreaks. The research and manufacturing of these products necessitate severe viral inactivation techniques to ensure safety and efficacy, making this market an important user of viral inactivation technology. Furthermore, continued efforts to improve vaccine development, particularly in response to new infectious illnesses, as well as increased investment in biopharmaceutical R&D, help to drive the segment's importance.

Viral Inactivation Market, By End-User

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Academic Research Institutes
• Others

Based on End-User, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, and Others. The pharmaceutical & biotechnology companies segment is estimated to dominate the market over the forecast period due to these companies' critical roles in the development, production, and commercialization of biopharmaceuticals such as vaccines, therapeutic proteins, and monoclonal antibodies, all of which require stringent viral inactivation processes to ensure safety and efficacy. The continued rise of biopharmaceutical research and development, combined with increased investments in biologic drug discovery, is driving demand for viral inactivation technologies in this market.

Key Players

• The "Global Viral Inactivation Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Merck KGaA, Danaher Corporation, Sartorius AG, Charles River Laboratories, Clean Cells, Rad Source Technologies, Texcell, Viral Inactivated Plasma Systems SA, WuXi PharmaTech, Parker Hannifin Corporation, SGS SA, Thermo Fisher Scientific, Bio-Rad Laboratories, GE Healthcare, MilliporeSigma, Lonza Group, and Catalent.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Viral Inactivation Market Recent Developments
• In May 2022, Pall Corporation established a partnership with RD-Biotech to produce vast volumes of Good Manufacturing Practice (GMP)-grade plasmid DNA (pDNA). The partnership seeks to fulfill the growing demand for gene and mRNA-based therapeutics, particularly for COVID-19 vaccine development.
• In January 2021, Akron Biotechnology announced an exclusive global deal with Octapharma to manufacture virally inactivated Human AB Serum derived from Octaplas(R) for cell therapy. This alliance intends to improve the safety of human serum against viruses, particularly COVID-19, and support research and development for commercialization.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL VIRAL INACTIVATION MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL VIRAL INACTIVATION MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL VIRAL INACTIVATION MARKET, BY METHOD

• 5.1 Overview
• 5.2 Solvent Detergent Method
• 5.3 Pasteurization
• 5.4 Others

6 GLOBAL VIRAL INACTIVATION MARKET, BY PRODUCT

• 6.1 Overview
• 6.2 Kits and Reagents
• 6.3 Services
• 6.4 Systems and Accessories

7 GLOBAL VIRAL INACTIVATION MARKET, BY APPLICATION

• 7.1 Overview
• 7.2 Blood & Blood Products
• 7.3 Cellular & Gene Therapy Products
• 7.4 Stem Cell Products
• 7.5 Tissue & Tissue Products
• 7.6 Vaccines and Therapeutics

8 GLOBAL VIRAL INACTIVATION MARKET, BY END-USER

• 8.1 Overview
• 8.2 Pharmaceutical and Biotechnology Companies
• 8.3 Contract Research Organizations
• 8.4 Academic Research Institutes
• 8.5 Others

9 GLOBAL VIRAL INACTIVATION MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 U.K.
  • 9.3.3 France
  • 9.3.4 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.5 Rest of the World
  • 9.5.1 Latin America
  • 9.5.2 Middle East and Africa

10 GLOBAL VIRAL INACTIVATION MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Ranking
• 10.3 Key Development Strategies

11 COMPANY PROFILES

• 11.1 Sartorius AG
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 Clean Cells
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 Danaher Corporation
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Charles River Laboratories
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 Merck KGaA
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 Rad Source Technologies
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 Parker Hannifin Corporation
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 Viral Inactivated Plasma Systems SA
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
• 11.9 SGS SA
  • 11.9.1 Overview
  • 11.9.2 Financial Performance
  • 11.9.3 Product Outlook
  • 11.9.4 Key Developments
• 11.10 Texcell
  • 11.10.1 Overview
  • 11.10.2 Financial Performance
  • 11.10.3 Product Outlook
  • 11.10.4 Key Developments

12 Appendix

• 12.1 Related Research